ONGENTYS (opicapone) for the Treatment of Parkinson’s Disease
Neurocrine Biosciences acquired rights from BIAL for the development and commercialisation of ONGENTYS in the US and Canada. Credit: Neurocrine Biosciences Inc.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more